The company designs and prints DNA to build microorganisms for use in everything from fragrances to living medicines. The latest round of investment comes from Viking Global and Y Combinator’s Continuity Fund, reports SynBioBeta. The funds are being used to support Ginkgo’s Bioworks3, the company’s third foundry for building engineered organisms. As for what else is in the company’s future, Ginkgo CEO Jason Kelly said:
We are agnostic as to where synthetic biology technologies can be best applied. We are partner-driven in our focus, as our goal is to build a platform upon which a wide range of biological products can be developed. Think of us like the Amazon Web Services of biology. We are not pursuing any specific application, but are making it easier for anybody to engineer biology using our platform. We are especially interested in working with startups who have an interesting application of synthetic biology in mind, but might not have the space or equipment to develop it.